Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

Sanofi, RadioMedix, and Orano Med Partner on Next-Generation Radioligand Therapy for Rare Cancers

NextEdge Admin

13 Sep 2024

2 min 2 sec

RadioMedix,Orano Med,radioligand medicine

Sanofi has entered an exclusive licensing agreement with RadioMedix, Inc., a U.S. clinical-stage biotech firm specializing in radiopharmaceuticals, and Orano Med, a French subsidiary of Orano Group focused on radioligand therapies (RLTs) for cancer treatment. The collaboration centers on AlphaMedix™ (212Pb-DOTAMTATE), a targeted alpha therapy (TAT) being evaluated for treating patients with metastatic, progressive neuroendocrine tumors (NETs) that express somatostatin receptors.

AlphaMedix™ is a peptide complex radiolabeled with lead-212 (212Pb), an alpha particle generator. Early clinical results showed a 62.5% durable response rate in reducing tumor burden, leading to its Breakthrough Therapy Designation by the U.S. FDA for gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Sanofi's Chief Medical Officer, Dietmar Berger, highlighted the potential of 212Pb as a transformative therapy for rare cancers, while Ebrahim S. Delpassand, CEO of RadioMedix, emphasized its role in pioneering nuclear oncology. Orano Med CEO Julien Dodet affirmed their commitment to advancing 212Pb-based therapies, developing a global platform for AlphaMedix™ manufacturing and distribution.

Sanofi will oversee global commercialization, while Orano Med handles manufacturing. The deal includes an upfront payment of €100 million, up to €220 million in sales milestones, and tiered royalties, pending regulatory approval. This agreement aligns with Sanofi's strategic focus on innovation in oncology, addressing hard-to-treat cancers through targeted therapies.